“Evaluation of the efficacy of bevacizumab in recurrence metastatic ovarian cancer as a second-line and beyond”, Tuj-hlth, vol. 44, no. 1, pp. 49–57, Mar. 2022, Accessed: Nov. 02, 2026. Available: https://journal.latakia-univ.edu.sy/index.php/hlthscnc/article/view/12000